Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.44 |
| ▸ | FLT1 | P17948 | 5/20 | 0.44 |
| ▸ | FLT4 | P35916 | 5/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351092 | 0.95 | EHMT2 (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL20351014 | 0.93 | EHMT2 (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| Trifluoroacetic Acid SCHEMBL20336945 | 0.88 | WHR1 (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL20347556 | 0.86 | RET (0.43) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL20347507 | 0.85 | RET (0.43) | EGFRKDRFGFR1FLT1FLT4 | |
| Formic Acid SCHEMBL20336805 | 0.82 | EHMT2 (0.50) | EHMT2DNMT1NSD2 | |
| Formic Acid SCHEMBL20303978 | 0.80 | SPIN1 (0.51) | EHMT2DNMT1NSD2 | |
| SCHEMBL20336804 | 0.80 | ABL1 (0.35) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL20303993 | 0.80 | KDR (0.50) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL20303751 | 0.80 | SRC (0.47) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3558971-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EGFR 4854/4885KDR 4621/4885FGFR1 4823/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EGFR 4205/4885KDR 2905/4885FGFR1 3115/4885 |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EGFR 4854/4885KDR 4621/4885FGFR1 4823/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EGFR 4209/4885KDR 2896/4885FGFR1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.